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Telomere homeostasis, a process that is essential for
continued cell proliferation and genomic stability, is
regulated by endogenous telomerase and a collection of
associated proteins. In this paper, a protein called KIP
(previously reported as a protein that binds specifically
to DNA-dependent protein kinase), has been identified
as a telomerase-regulating activity based on the follow-
ing pieces of evidence. First, complexes between KIP
and the catalytic subunit of telomerase (hTERT) were
identified using the yeast two-hybrid technique. Second,
antibodies specific to KIP immunoprecipitate human
telomerase in cell-free extracts. Third, immunolocaliza-
tion experiments demonstrate that KIP is a nuclear pro-
tein that co-localizes with hTERT in cells. Fourth, KIP
binds to hTERT both in vitro and in vivo in the absence
of human telomerase RNA or telomeric DNA, thus defin-
ing the catalytic subunit of telomerase as the site of
physical interaction. Fifth, co-immunoprecipitation ex-
periments suggest that KIP-hTERT complexes form
readily in cells and that overexpression of KIP in telo-
merase-positive cells increases endogenous telomerase
activity. Finally, continued overexpression of KIP (60
population doublings) resulted in cells with elongated
telomeres; thus, KIP directly or indirectly stimulates
telomerase activity through hTERT and contributes to
telomere lengthening. The collective data in this paper
suggest that KIP plays a positive role in telomere length
maintenance and/or regulation and may represent a
novel target for anti-cancer drug development.
Telomeres are essential and functional components of the
physical ends of eukaryotic chromosomes. They are composed
of a repetitive DNA sequence (TTAGGG in vertebrates) and
associated proteins (1–3). In the absence of functional telomere
maintenance pathways, dividing cells show a progressive loss
of telomeric DNA during successive rounds of replication due to
a DNA end replication problem (4); thus, telomere shortening
has been proposed as a ticketing mechanism that controls the
replicative capacity of cells and cellular senescence (5). Cells
with extended replicative life spans have mechanisms to coun-
teract the loss of telomeric DNA. In some immortalized cells,
for example, telomere shortening is alleviated by telomerase, a
ribonucleoprotein enzyme that adds short repetitive telomeric
sequences to the 3-chromosomal ends by reverse transcription
(6, 7).
Telomerase activity is expressed in a majority of human
tumors but not in normal somatic cells (8). The introduction of
the telomerase catalytic subunit gene into normal somatic cells
prevents telomere erosion and senescence and extends their
proliferative life span (9). Conversely, the inhibition of the
telomerase activity results in telomere shortening and subse-
quent growth arrest of cancer cells followed by senescence or
cell death (10, 11). Genetic disruption of the telomerase RNA
component also causes telomere erosion and chromosomal ab-
errations, resulting in functional defects in organs containing
highly proliferative cells (12, 13). These observations indicate
that telomerase activity is necessary for the proliferation of
primary and transformed cells and that the activation of telo-
merase may be a pivotal step in human carcinogenesis.
The human telomerase complex contains a catalytic subunit
of reverse transcriptase (hTERT)1 and an integral RNA (hTR).
Both hTERT and hTR are essential for assembly of functional
telomerase activity in vitro and in vivo (6, 7). In human cells,
several proteins have been identified that associate with telo-
merase. The chaperone proteins p23 and Hsp90 associate with
hTERT and are involved in the assembly of telomerase activity
(14). Telomerase-associated protein 1 interacts with both
hTERT and hTR but is apparently not required for telomerase
activity (15–17). The 14-3-3 signaling protein is required for
efficient accumulation of hTERT in the nucleus (18). PinX1,
identified as the Pin2-terminal restriction fragment 1 (TRF1)-
interacting partner, is a potent catalytic inhibitor of telomerase
and binds directly to hTERT (19). Recently, the Ku complex
was shown to associate with telomerase through interaction
with hTERT and this interaction may regulate telomerase ac-
cess to telomeric DNA ends (20). Because native human telo-
merase has an estimated mass of 1,000 kDa, other as yet
unidentified hTERT-associated proteins are likely to be pres-
ent and physiologically relevant to telomere transactions.
In a search for proteins capable of interacting with human
telomerase, we identified KIP (a DNA-PKcs-interacting pro-
tein) as an hTERT-interacting protein using the yeast two-
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hybrid screening assay. GST pull-down and immunoprecipita-
tion analyses reveal that KIP interacts with telomerase by
binding to the catalytic subunit hTERT both in vitro and
in vivo. KIP appears to function as a positive modulator in
telomere homeostasis.
EXPERIMENTAL PROCEDURES
Expression Vectors—The KIP-V5 expression vector was constructed
by inserting the EcoRI and XhoI fragments from the full-length KIP
cDNA (generated by PCR with the appropriate synthetic primers) into
pcDNA3.1/V5-His (Invitrogen). The hTERT-HA expression vector (gen-
erously provided by H. Seimiya, Japanese Foundation for Cancer Re-
search) was constructed by cloning the full-length hTERT cDNA into
pCR3 vector (18). The expression vector for GST-KIP was constructed
by cloning the EcoRI and XhoI fragments from the full-length KIP
cDNA into pGEX-5X-1 (Amersham Biosciences). The GST fusion pro-
tein was expressed and purified by glutathione-Sepharose column chro-
matography according to the manufacturer’s instructions.
Yeast Two-hybrid Screening—Yeast two-hybrid screening was per-
formed as described previously (21). The yeast strain EGY48 harboring
pLexA-hTERT and pSH18-34 was transformed by the lithium acetate
method with a HeLa cDNA library fused to the activation domain vector
pB42AD (Clontech).
Cell Lines and Culture Conditions—The human lung carcinoma cell
line H1299 and the human breast cancer cell line MCF7 were cultured
in RPMI 1640 medium, and the human fibrosarcoma cell line HT1080
and human embryonic kidney cell line 293T were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 g/ml streptomycin in 5% CO2 at 37 °C.
To establish cell lines stably expressing KIP, the KIP-V5 construct was
transfected into MCF7 cells. As a control, MCF7 cells were also stably
transfected with an empty vector. Multiple independent single clones
were isolated and checked for protein expression by immunoblotting
analysis with anti-KIP or anti-V5 antibodies.
Production of Antibodies—To raise antibodies against KIP, rabbits
were immunized with recombinant KIP prepared by cleaving GST-KIP
with Factor Xa followed by the removal of the cleaved GST and un-
cleaved GST-KIP with glutathione-Sepharose. Anti-KIP antibodies
were affinity-purified on KIP coupled to CNBr-activated Sepharose 4B
(Amersham Biosciences).
GST Precipitation, Immunoprecipitation, and Immunoblotting Anal-
yses—The KIP-V5 and hTERT-HA expression vectors were transfected
into H1299 cell line using LipofectAMINE (Invitrogen) according to the
manufacturer’s protocol. Cells were suspended in lysis buffer (10 mM
Tris-HCl, pH 7.5, 5 mM MgCl2, 50 mM KCl, 0.01% Nonidet P-40, 20%
glycerol, 0.1 mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol),
incubated on ice for 30 min, and sonicated at 50 J/watt s for three 5-s
pulses. Lysates were then centrifuged at 12,000 rpm for 30 min to
remove insoluble material. For GST pull-down experiments, lysates
were precleared with glutathione-Sepharose 4B and incubated with
glutathione-Sepharose beads containing GST-KIP or control GST for
2 h at 4 °C. For immunoprecipitation, lysates were preincubated with
protein G-Sepharose and incubated with primary antibodies precoupled
to protein G-Sepharose beads for 2 h at 4 °C. The precipitated proteins
were washed extensively and subjected to immunoblot analysis. Im-
munoprecipitation and immunoblot analyses were performed using
anti-HA (Santa Cruz Biotechnology), anti-V5 (Invitrogen), anti-DNA-
PKcs (NeoMarkers), and anti-KIP antibodies. Immunoprecipitation for
telomeric repeat amplification protocol (TRAP) assays was performed
using anti-KIP, anti-V5, anti-p53 (Santa Cruz Biotechnology), anti-
TRF2 (Santa Cruz Biotechnology), and anti-RTBP1 (rice telomere-bind-
ing protein) antibodies as primary antibodies.
Telomerase Assays—The TRAP was used as previously described
(10). Immunoprecipitated proteins were added to telomerase extension
reactions and incubated for 20 min at 37 °C. Reactions were stopped by
heating at 94 °C for 90 s and placed on ice. PCR was performed using
the TS primer and ACX primer for 30 cycles (denaturation at 94 °C for
30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s). As an
internal telomerase assay standard, NT and TSNT primers were added
to the PCR mixture as previously described (22). Telomerase products
were resolved by electrophoresis on a 10% nondenaturing polyacryl-
amide gel. Bands were then visualized by staining with SYBR Green
(Molecular Probes). The signal intensity was quantified with a LAS-
1000 Plus Image analyzer (Fuji Film).
TRF Analysis—To measure the telomere length, genomic DNA was
digested with RsaI and HinfI and separated on 0.7% agarose gel.
DNA samples were transferred to a nylon membrane (Hybond N,
Amersham Biosciences) and hybridized with a 32P-labeled probe, (TT-
AGGG)20. Signals were quantified by phosphorimaging.
RESULTS
Identification of KIP as an hTERT-interacting Partner—To
identify hTERT-interacting factors, we screened a HeLa cell
cDNA library using the yeast two-hybrid system. The cDNA
library was cloned into a vector (pB42AD) containing a tran-
scriptional activation domain. We constructed a plasmid vector
(pLexA/hTERT-(762–855)) that expressed a fusion protein
with the DNA-binding domain of the LexA protein and hTERT
reverse transcriptase motifs (amino acids 762–855, see Fig. 1A)
(23, 24). Transformation of pLexA/hTERT762–855 alone (the
“bait”) into yeast strain EGY48 did not activate lacZ transcrip-
tion. Of 3.5  106 clones screened, 21 positive clones were
obtained and sequenced, resulting in an isolation of eight in-
dependent clones encoding a gene subsequently identified as
KIP. Full-length KIP did not result in transcriptional activa-
tion of the reporter gene when tested against the hTERT region
spanning amino acids 856–944 or with a heterologous DNA-
binding protein (Fig. 1B, TOP3). KIP was previously identified
as a protein that binds specifically to the upstream kinase
domain of DNA-PKcs (25). Additionally, KIP was reported as a
calcium and integrin-binding protein (26). KIP displays signif-
icant homology to calcineurin B and calmodulin, which contain
two EF-hand motifs that correspond to the calcium-binding
domains. The mouse KIP cDNA encodes a protein 95% identical
to the human protein (27).
To map the region in KIP that interacts with hTERT, yeast
strain EGY48 was co-transformed with pLexA/hTERT-(762–
855) and pB42AD plasmids containing various regions of KIP
(Fig. 2A). Only full-length KIP was found to associate with
hTERT based on yeast two-hybrid as an end point assay
(Fig. 2B).
hTERT-KIP Binding in Vitro and in Vivo—To confirm the
direct interaction between hTERT and KIP, we analyzed the
binding of hTERT and KIP fused to glutathione S-transferase
(GST). When H1299 cells were transfected with hTERT-HA
expression construct and subjected to GST pull-down experi-
ments, GST-KIP but not the control GST precipitated
hTERT-HA from cell extracts (Fig. 3A). These results indicate
that KIP interacts with hTERT in vitro. To further determine
whether hTERT and KIP associate in vivo, H1299 cells were
FIG. 1. Interaction of hTERT with KIP. A, schematic representa-
tion of hTERT bait constructs. Open boxes represent the regions used to
test for physical binding to hTERT. Values in parentheses indicate the
positions of amino acid residues. Locations of telomerase-specific motif
(T) and conserved reverse transcriptase motifs (1, 2, and A–E) are
indicated by gray boxes. B, analysis of the physical interaction between
hTERT and KIP using the yeast two-hybrid assay. In this experiment,
binding to full-length KIP (residues 1–191) was analyzed. LexA and
topoisomerase III (TOP3) were used as negative controls. The blue
signal on the SG-HWU/X plate and the growth on the SG-HWUL plate
indicate activation of the reporter genes, LacZ and LEU2, respectively.
S, synthetic; G, galactose; D, glucose; H, histidine (); W, tryptophan
(); U, uracil, (); L, leucine (); X, X-gal (5-bromo-4-
chloro-3-indolyl--D-galactopyranoside).















cotransfected with hTERT-HA and KIP-V5 expression con-
structs (Fig. 3B) and subjected to immunoprecipitation with
anti-HA or anti-V5 antibodies followed by immunoblot analy-
sis. KIP-V5 was detected in anti-HA immunoprecipitates only
when both hTERT-HA and V5-KIP proteins were expressed.
Likewise, hTERT-HA was recovered in anti-V5 immunopre-
cipitates, indicating that KIP interacts with hTERT in mam-
malian cells (Fig. 3C). Subcellular distribution of KIP and
hTERT was examined in co-transfected H1299 cells by immu-
nofluorescence. Both proteins were clearly localized in the nu-
cleus of the cell as expected. In addition, KIP appears to co-
localize with hTERT in distinct subnuclear pockets of
fluorescence (Fig. 3D).
KIP Association with Telomerase—Because KIP interacts
with hTERT in vitro and in vivo, we next examined KIP bind-
ing to catalytically active telomerase. Cell lysates were pre-
pared from 293T, HT1080, or H1299 cells, immunoprecipitated
with a KIP-specific antibody, and analyzed for telomerase ac-
tivity by the TRAP assay. As shown in Fig. 4, the anti-KIP
antibody immunoprecipitated telomerase activity from the
three telomerase positive cell lines. We observed no telomerase
activity when cell lysates were immunoprecipitated with con-
trol antibodies against TRF2, p53, and RTBP1 (28).
To explore the possibility that anti-KIP antibody may bind
nonspecifically to telomerase, H1299 cells were transfected
with the KIP-V5 expression construct (or the empty vector) and
immunoprecipitated with anti-V5 antibody. Telomerase activ-
ity was detected in the immunoprecipitates from cells express-
ing KIP-V5 but not from the empty vector-expressing cells (Fig.
4D). Note that the KIP-V5-transfected cells express signifi-
cantly higher levels of KIP relative to the endogenous KIP gene
(see also Fig. 6A); therefore, the amount of telomerase activity
recovered by anti-V5 antibody was reproducibly higher relative
to that recovered using anti-KIP antibody in H1299 cells ex-
pressing the endogenous gene (compare Fig. 4D, lane 3, with
Fig. 4C, lane 3). Taken together, these results indicate that KIP
associates physically with telomerase through interaction with
hTERT in vivo and that this association is probably specific.
Analysis of DNA-PKcs Complexes with KIP and hTERT—As
noted above, KIP was originally identified as a DNA-PKcs-
interacting protein using a two-hybrid screening (25). To ex-
plore the interaction between KIP and DNA-PKcs in mamma-
lian cells, H1299 cells were co-transfected with KIP-V5 and
hTERT-HA and analyzed for interaction with DNA-PKcs. Fig.
5A shows a control experiment documenting ectopic expression
of KIP-V5 and hTERT-HA in these cells along with endogenous
DNA-PKcs expression. We tested whether anti-DNA-PKcs an-
tibody would precipitate KIP-V5 and/or hTERT-HA. KIP-V5
was detected in anti-DNA-PKcs immunoprecipitates from KIP-
V5-transfected cells but not from the empty vector-transfected
cells (Fig. 5B, top panel, lanes 4 and 5), indicating that KIP
interacts with DNA-PKcs in mammalian cells. An analysis of
DNA-PKcs immunoprecipitates in cells expressing both
KIP-V5 and hTERT-HA revealed the presence of KIP-V5 (Fig.
5B, top panel, lane 2); however, DNA-PKcs pull-down experi-
ments of this type did not recover detectable levels of
hTERT-HA (Fig. 5B, bottom panel, lane 2). We also observed
that DNA-PKcs immunoprecipitates contained much less
KIP-V5 in cells co-transfected with both hTERT-HA and
KIP-V5 relative to cells expressing only KIP-V5 (Fig. 5B, top
panel, compare lanes 2 and 4). To further examine the binding
of hTERT and DNA-PKcs to KIP, we expressed both KIP-V5
and hTERT-HA in H1299 cells and performed immunoprecipi-
tations with anti-V5 or anti-HA antibodies. As shown in Fig.
5C, DNA-PKcs was detected in anti-V5 immunoprecipitates
from cells expressing KIP-V5 (lanes 2 and 4). As in Fig. 5B, the
amount of DNA-PKcs recovered by immunoprecipitation was
reduced in cells expressing both hTERT-HA and KIP-V5 com-
pared with cells expressing only KIP-V5 (Fig. 5C, compare
FIG. 3. Interaction between hTERT and KIP in vivo and in
vitro. A, GST or GST-KIP proteins were immobilized on glutathione-
Sepharose and incubated with cell extracts containing hTERT-HA.
Bound proteins were detected by immunoblotting with anti-HA anti-
body as described under “Experimental Procedures.” B, expression of
hTERT-HA and KIP-V5. H1299 cells were co-transfected with
hTERT-HA and KIP-V5 expression constructs and subjected to immu-
noblotting with anti-HA or anti-V5 antibodies. C, in vivo binding anal-
ysis by co-immunoprecipitation (IP) of hTERT and KIP. H1299 cells
were co-transfected with hTERT-HA and KIP-V5 expression constructs
and subjected to immunoprecipitation with anti-HA or anti-V5 antibod-
ies followed by immunoblotting with anti-V5 or anti-HA antibodies. D,
immunofluorescence analysis of H1299 cells co-transfected with
hTERT-HA and KIP-V5 expression constructs. Fixed cells were incu-
bated with anti-HA and anti-V5 antibodies followed by staining with
fluorescein isothiocyanate-conjugated goat anti-rabbit (green, corre-
sponding to hTERT) and rhodamine-conjugated goat anti-mouse (red,
corresponding to KIP) antibodies. Protein localization was analyzed
using a confocal microscope.
FIG. 2. Analysis of KIP deletion mutants and hTERT binding.
A. schematic representation of KIP mutants compared with wild type
full-length KIP (KIP-F). Open boxes represent the regions used in this
analysis. Values in parentheses indicate the positions of amino acid
residues. Locations of two EF hands are indicated by gray boxes. B, KIP
mutants compared with wild type KIP-F were analyzed by the yeast
two-hybrid assays. Unrelated topoisomerase III (TOP3) “prey” is used
as a negative control. The blue signal and the yeast growth are de-
scribed in the legend of Fig. 1. S, synthetic; G, galactose; D, glucose; H,
histidine (); W, tryptophan (); U, uracil, (); L, leucine (); X, X-gal
(5-bromo-4-chloro-3-indolyl--D-galactopyranoside).















lanes 2 and 4). DNA-PKcs was not detected in anti-HA immu-
noprecipitates from cells expressing hTERT-HA (Fig. 5C, lanes
6 and 7). These data are consistent with the idea that KIP
interacts specifically with DNA-PKcs (25); however, DNA-PKcs
does not appear to form detectable and/or stable complexes
with soluble hTERT.
Overexpression of KIP in MCF7 Cells Increases Telomerase
Activity—Because KIP associates physically with telomerase in
vivo, we examined whether KIP affects telomerase activity. We
established MCF7 cell lines stably expressing KIP-V5 (or an
empty vector negative control). Levels of endogenous and ec-
topically expressed KIP proteins were examined by immuno-
blotting using anti-KIP and anti-V5 antibodies (Fig. 6A). As
noted above, the ectopic expression of KIP-V5 was 10-fold
greater than the endogenous KIP gene. Cells expressing
KIP-V5 and the empty vector grew normally and exhibited no
FIG. 4. KIP associates physically with telomerase. A–C, cell lysates from 1  106 cells were prepared from 293T, HT1080, or H1299 cell lines
and subjected to immunoprecipitation (IP) with the anti-KIP, anti-TRF2, anti-p53, and anti-RTBP1 antibodies. Immunoprecipitates were analyzed
for telomerase activity by the TRAP assay as described under “Experimental Procedures.” Aliquots equivalent to 50,000 cells were loaded from the
TRAP assays. The input lane corresponds to telomerase activity present in 2.5  103 cells. Lanes labeled LB correspond to the negative control
(lysis buffer only). ITAS represents the internal telomerase assay standard. D, H1299 cells were transfected with KIP-V5 expression construct or
the empty vector and subjected to immunoprecipitation with anti-V5 antibody. The immunoprecipitates were analyzed for telomerase activity by
the TRAP assay.
FIG. 5. Interaction of KIP with DNA-PKcs and hTERT. A, H1299 cells were co-transfected with KIP-V5 and hTERT-HA expression
constructs (marked by  or  above each lane) followed by immunoblotting with anti-V5 (top panel), anti-HA (middle panel), or anti-DNA-PKcs
antibodies (bottom panel). The latter antibody probe was used to detect endogenous levels of DNA-PKcs in these cells. B, H1299 cells were
co-transfected as indicated (marked by  or  above each lane) and subjected to immunoprecipitation (IP) with anti-DNA-PKcs antibody followed
by immunoblotting with the anti-KIP-V5 (top panel) or anti-hTERT-HA (bottom panel) antibody probes. The asterisk marks the position of
nonspecific immunoglobulin chains. C, H1299 cells were transfected with hTERT-HA or KIP-V5 as indicated (marked by  or  above each lane)
and subjected to immunoprecipitation with anti-V5 or anti-HA antibodies as marked above the horizontal lines at the top of the blot. The recovered
proteins were than analyzed by immunoblotting with anti-DNA-PKcs antibody probe.















detectable differences in growth rates or morphology over 60
population doublings. After 60 population doubling, we com-
pared telomerase activity in stable cell lines expressing KIP-V5
and the empty vector. Telomerase activity in KIP-V5 cells was
increased by roughly 2-fold relative to the control cell lines (Fig.
6, B and C). These results suggest that KIP acts as a positive
regulator of telomerase; however, it is not clear whether an
increase in telomerase activity by KIP was due to the direct
effect of telomerase enzyme per se or to a KIP-related increase
in the expression of hTERT or hTR genes. To address this
issue, the impact of KIP on gene expression of hTERT and hTR
was evaluated (29). We observed no significant differences in
steady-state levels of hTERT mRNA or hTR transcripts in cell
lines expressing KIP-V5 or the empty vector (Fig. 6D).
Overexpression of KIP in MCF7 Cells Increases Telomere
Length—To examine whether a KIP-mediated increase in telo-
merase activity was attended by changes in telomere lengths,
we performed a TRF analysis. Control cells (MCF7 cells with or
without vector) exhibited an average telomere length of
roughly 5 kb with most fragments spread over a range of 3–8
kb (Fig. 6E). Telomeres were clearly elongated in the clones
expressing KIP-V5 with an increase in TRF length to 10 kb or
more and spanning down to roughly 5 kb. These findings sug-
gest that KIP exerts a positive role in telomere maintenance
and/or regulation.
DISCUSSION
KIP interacts with hTERT both in vitro and in vivo and is
found to associate with the telomerase complex. Overexpres-
sion of KIP in telomerase-positive cells stimulates telomerase
activity. The possibility that KIP stimulates hTERT or hTR
gene expression, thereby leading to elevated levels of endoge-
nous telomerase, was ruled out by showing that steady-state
levels of mRNA were not altered by KIP overexpression. A
direct or indirect consequence of high level KIP expression is
the longer average telomere lengths. Because KIP is a nuclear
protein that co-localizes with hTERT, our collective results
strongly suggest that KIP positively regulates telomerase and
telomere length.
A number of factors have been identified that associate with
mammalian telomeres and telomerase. PinX1, identified as a
Pin2-TRF1-binding protein, interacts with hTERT and directly
inhibits telomerase activity (19). The expression of PinX1 re-
sults in progressive telomere shortening followed by cellular
senescence. It is conceivable that KIP and PinX1 are counter-
acting proteins that act to regulate an equilibrium level of
telomerase activity required for the replicative capacity of cells.
Although KIP was first identified as a novel DNA-PKcs-inter-
acting protein (25), little is known regarding the physiological
role of this interplay. KIP is expressed ubiquitously in many
tissues in the embryo (25, 27), suggesting a role in develop-
ment. Telomerase activity is necessary for the continuous pro-
liferation of many tumor cells, and because KIP appears to
positively influence telomerase and telomere length, this pro-
tein may represent a novel drug target in cancer. Moreover, its
role in cellular senescence is also relevant to our understanding
of aging. For example, improper expression of KIP could ele-
vate or repress telomerase activity in cells. It is also possible
that KIP-hTERT interactions could be altered by the presence
(and amount) of other KIP-interactive partners, thereby titrat-
ing telomerase activity up or down. Because conserved KIP
homologs are present in other eukaryotes (25), KIP might rep-
resent a general mechanism for regulating telomerase activity.
We demonstrate that overexpression of KIP in telomerase-
positive MCF7 cells increases telomerase activity and telomere
length. We also expressed the KIP cDNA in an antisense ori-
entation to deplete the endogenous protein. Among the clones
that displayed reduced KIP expression, we observed unambig-
uous decreases in TRF length (data not shown). Unfortunately,
these clones were unstable and, for this reason, were not in-
cluded in the current study; however, these findings under-
score the notion that the KIP concentration is important to the
cell in maintaining telomere lengths in vivo. The critical ques-
tion that remains to be answered is how KIP regulates telo-
merase activity and telomere length in vivo. We do not have
any evidence that hTERT binds directly to DNA-PKcs, and we
did not detect formation of a ternary complex (KIP/DNA-PKc/
hTERT). Detection of these sorts of soluble complexes should be
feasible using our experimental approach; however, the ab-
sence of evidence does not mean that such complexes do not
exist (or they may exist only in a chromatin context). The data
in Fig. 5B further suggest that KIP binding to DNA-PKcs is
somehow influenced by the presence of hTERT. It is possible,
for example, that KIP can shuttle between the DNA-PK com-
plex and telomerase. Differential binding of KIP in this case
suggests a mechanism to regulate the positive action of KIP on
telomerase as noted above. Alternatively, KIP may simply play
multifunctional roles in diverse or intersecting pathways in the
cell, because it binds other proteins as well (26).
It was recently reported that DNA-PKcs deficiency severely
disrupts telomere “capping” without affecting telomere length,
suggesting that DNA-PKcs plays a critical role in capping (30,
FIG. 6. Overexpression of KIP increases telomerase activity
and telomere length in MCF7 cells. A, MCF7 cells were stably
transfected with KIP-V5 or a vector control. Endogenous and ectopically
expressed KIP was detected by immunoblotting (Western Blotting
(WB)) with anti-KIP (top panel) or anti-V5 (bottom panel) antibodies. B,
MCF7 cells stably transfected with KIP-V5 (or empty vector) were
harvested after 60 population doubling, and telomerase activities were
measured by using the TRAP assay. Lane labeled LB corresponds to a
lysis buffer only negative control. ITAS marks the internal telomerase
assay standard. C, telomerase products were quantified with the
mean  S.D. from three independent experiments identical to panel B.
D, representative results of RT-PCR analysis for the expression of
hTERT and hTR in stable MCF7 cell lines. RT-PCR products from each
sample were normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) signal. E, stable MCF7 cells were harvested at 60 population
doubling, and genomic DNA was digested with RsaI and HinfI followed
by Southern blotting using a telomere repeat probe (right panel). The
gel was stained with ethidium bromide to ensure equal loading of
genomic DNA (left panel).















31). It is possible that KIP regulates telomere length through
telomerase-KIP interaction as opposed to DNA-PK/KIP inter-
action, and proper capping may require both interactions (32).
DNA-PKcs may actually be involved in telomere length regu-
lation (33, 34) based on studies that severe combined immuno-
deficiency mice have elongated telomeres compared with wild-
type mice (35). Although the mutant DNA-PKcs protein in
severe combined immunodeficiency cells is unstable, it is still
present at detectable levels (36, 37). Mutant DNA-PKcs in
severe combined immunodeficiency mice might interact differ-
ently (or not at all) with KIP, thereby leading to alterations in
equilibrium binding of KIP and hTERT. One cannot rule out
the prospect that low DNA-PKcs levels promote higher KIP-
hTERT complex formation leading to progressive lengthening
of telomeres as seen when KIP is overexpressed in cell lines
(Fig. 6). Clearly, other as yet unidentified factors could be
involved in the regulation of telomerase activity and telomere
length by KIP and a competition based binding model is highly
speculative.
The recent finding that DNA-PKcs is localized to telomeric
DNA in vivo provides compelling evidence for a physiological
role in telomere function or regulation (38). Cells from mice
deficient in either the Ku subunit or DNA-PKcs display
genomic instability due to frequent telomere fusions, further
suggesting their essential roles in telomere function (33, 39,
40); however, the precise mechanism of their action is unclear.
Whereas the Ku complex associates with telomerase through
interaction with hTERT (20), we found no direct interaction of
DNA-PKcs with telomerase and, as noted above, our data do
not rule out the possibility that DNA-PKcs associates with
telomerase via KIP (but only in a chromatin context, for exam-
ple). Although this report is the first to show that KIP associ-
ates physically with telomerase, many questions remain re-
garding the physiological role of KIP-telomerase interaction
and how such a complex might be regulated if at all. Finally,
the subtle details on the possible interplay between KIP and
DNA-PKcs in the presence and absence of hTERT should lead
to a better understanding of how KIP is involved in telomere
biology during development, aging, and cancer.
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